Search Results for "hATTR"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
APOLLO Post-Hoc Analysis by Baseline Polyneuropathy Severity
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.
Insights from the phase 3 HELIOS-A study of vutrisiran in patients with hATTR-PN
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
This deck highlights data from the phase 3 HELIOS-A trial, including exploratory cardiac endpoints and post-hoc analyses.
NfL as a Potential Biomarker in hATTR Amyloidosis
This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.
This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.
